Consequently, their treatment regimens were changed and the EGFR T790M and PIK3CA mutations were no longer detectable in the tumor samples collected a couple of months later, and patients responded again to retreatment with an EGFR tyrosine kinase inhibitor. Here, PIK3CA is linked to neoplasm.